MiR-126: a novel route for natalizumab action?



Treatment, therapies and management:
MicroRNAs (miRNAs) are involved in post-transcriptional regulation of gene expression, exerting their effects on different aspects of immunity. A previous study showed differential miR-126 expression in CD4+T cells of untreated RRMS patients.

This study looks at the expression of miR-126 in 24 natalizumab-treated patients, 12 untreated patients and 12 healthy controls. The results showed miR-126 was down-regulated in patients on natalizumab treatment, while miR-126 was up-regulated during relapse in patients on natalizumab treatment.

It was also shown that miR-126 expression was associated with expression of POU2AF1. POU2AF1 is a regulator of Spi-B, which binds to the promoter region of JC virus (JCV). Inhibition experiments showed a link between the expression of miR-126 and POU2AF1/Spi-B. These results provide further insight into the mechanism of action of natalizumab, which helps us better understand the effects of natalizumab, as well as it side effect profile.


Authors: Meira M, Sievers C
Source: Mult Scler. 2014 Mar 5. [Epub ahead of print]
Read the abstract

 

Latest MS research news

Main MS research areas

Challenges of MS research

Atacicept in multiple sclerosis: a randomised, placebo-controlled, double-blind, phase 2 trial